EGFR and lung cancer: Lung cancer patients have intrinsic or acquire new EGFR mutations during treatment with small-molecule EGFR-inhibitors that complicate current treatment options highlighting the need for the development of novel strategies for EGFR-resistant NSCLC, including combined therapies with ICI or radiotherapy [10,126,127,128,129].